Practice

ACR 2026 – Day 2 Report https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB

ACR 2026 – Day 2 Report | RheumNow

@RheumNow The narrative medicine interactive session at #ACR2026 was well attended and had a lot of interesting exchange of thoughts and ideas. Holistic care of patients, attention to caregiver burnout and ensuring provider well being is the need of the hour in rheumatology.

#ACR26 #2965: AI-generated answers to common pt Qs were rated similarly to rheumatologist-written answers. The highest-value approach, was AI plus rheumatologist review, which improved utility, readability, and completeness. The future may be hybrid, not human versus AI.@RheumNow

RheumNow’s expanded #ACR26 coverage is sponsored by UCB. All coverage content is independently selected by RheumNow and its faculty.

Article

Two Prescriptions, One Patient

Antoni Chan, MD, PhD Nov 11, 2026

Obesity, in particular in psoriatic arthritis (PsA) was widely covered at #ACR26. This is from the recognition of the size of the problem.

Inboxology: specialty needing more attention Abstract 2951 quantified non-EHR visit time among pediatric rheumatologists Vs national median: 1)patient msgs/day 5.1 vs 2.1 2)total inbasket time/day: 28.6 vs 14 mins 3)EHR time outside clinic/week: 322 vs 222 mins @RheumNow #ACR26 https://t.co/20GG8EmwnU

https://x.com/AkhilSoodMD/status/2120573016841285650/photo/1

RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by UCB. All coverage content is independently selected by RheumNow and its faculty.

RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.

@RheumNow Social determinants of health (SDOH) in rheumatology: Are we routinely screening for SDOH, and more importantly, how are we addressing the unmet needs identified? #ACR2026 Determinates of health and outcomes in rheumatic diseases #4

A#2944 ASAS Points to Consider for D2T and Rx-refractory axSpA: Verify dx, rule out mimics, confirm inflammation with CRP/MRI, check adherence, address comorbidities, add non-pharm care, and provide education. @RheumNow #ACR26 https://t.co/ETlqLSrj6J

@RheumNow Determinates of health and outcomes in Rheumatic diseases #3. Race & ethnicity in rheumatology guidelines: Clarify their role in recommendations, improve trial diversity to strengthen evidence, and do not restrict treatment options based on race or ethnicity. #ACR26

Fewer RA admissions, but more readmissions. US weighted index admissions fell 10541 in 2010 to 3901 in 2021; all-cause readmission rates rose 9.8% to 13.0%. Suggests hospitalized RA patients represent smaller but more medically complex population @Rheumnow #2924 #ACR26 https://t.co/WVUccpiELz

https://x.com/DrMiniDey/status/2120532501047157031/photo/1

Can AI answer our patients' rheumatology questions as well as we can? In Abstract 2965 at #ACR26, patients rated AI and rheumatologist answers similarly. But expert-reviewed AI performed particularly well. The human-in-the-loop may be the sweet spot. @RheumNow https://t.co/KWL7YPTnoG

https://x.com/bella_mehta/status/2120527970552963359/photo/1

RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Eli Lilly and Company. All coverage content is independently selected by RheumNow and its faculty.

How should race and ethnicity be used in rheumatology guidelines? On the final day of #ACR26, I’ll discuss the evidence alongside Sam Lim and Candace Feldman. Join us at 10-11am in W415A! @RheumNow https://t.co/VCHa4x5MlN https://t.co/KQKPmrxupf

Ab#2543 #ACR26 @RheumNow Survey of US Academic Rheums on Opioid Rx IMG trained - lower odds of opioid Rx <5 yrs since training less likely to prescribe, 10-20 yrs OR 5.2, 20-30 yrs OR 6.7 60% felt opioids have role in rheum pain mgmt 70% feel pressured by pts Dx: OA 41%, RA 28% https://t.co/Octn02lo3E

https://x.com/ericdeinmd/status/2120336069967114744/photo/1

@RheumNow abstract 2480. Can high-fidelity simulation help bridge gaps in pediatric rheumatology education? Pilot modules boosted learner confidence in core competencies. A promising approach to improve disease recognition and timely referrals amid workforce shortages! #ACR26

SLE can permanently alter employment. In a cohort 1800pts followed a median 18 years, 84.3% of pts initially receiving disability benefits remained in that state. Renal, neuropsychiatric, endocrine and musculoskeletal damage predicted disability. @rheumnow #ACR26 Abstract #1266 https://t.co/9tzmAlJcx1

https://x.com/bella_mehta/status/2120264232293831088/photo/1

RITAZAREM: Three Things I Learned about AAV Maintenance https://t.co/hFiPkWfDOr https://t.co/XZWVlAlpca

RITAZAREM: Three Things I Learned about AAV Maintenance | RheumNow

Article

ACR 2026 Day 3 Report

Jack Cush, MD Nov 10, 2026

Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:

Article

Menopause and Rheumatoid Arthritis: Are we asking enough?

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA Nov 10, 2026

Pain, fatigue and poor sleep are common concerns for people living with RA. In women approaching or experiencing menopause, joint and muscle pain, mood changes and sleep difficulties are recognised menopause-associated symptoms. A study from Mayo Clinic at this year’s ACR Convergence examines

Key takeaways for tx of hema manifestations in SLE: - asymptomatic leucopenia doesn’t always require tx w/ steroids or IS in the absence of systemic manifestations - r/o other etiologies - comanage w/ hematologist @RheumNow #ACR26 https://t.co/AXtDx4PZCO

https://x.com/RHEUMarampa/status/2120249141188350445/photo/1

RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by UCB. All coverage content is independently selected by RheumNow and its faculty.

Abstract 2732: How do rheumatologists use and edit AI-scribe generated documentation? - HPI use is more common: (76.4%) incl. ~ 50% w/ edits - A&P use is less common: 77.1% non-use - A&P use including edits rose over time #ACR26 @rheumnow https://t.co/bzTbvdLbEm

In 12 European countries (n=8,475 biologic-naive PsA starting TNFi): current smokers less likely to reach ACR20 at 12mo than never smokers (aOR 0.60, 95% CI 0.45-0.79), and ex-smokers slightly less (OR 0.76). Council for smoking cessation in PsA A#2312 @RheumNow #ACR26